HER2 Status by Standardized Immunohistochemistry and Silver-EnhancedIn SituHybridization in Korean Breast Cancer

Silver-EnhancedIn SituHybridization as an Alternative to FluorescenceIn SituHybridization for Assaying HER2 Amplification in Clinical Breast Cancer

(2012) Kyeongmee Park et al.   Journal of Breast Cancer

Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization

(2011) Seho Park et al.   CANCER

Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization for HER2 Gene Status in Breast Carcinomas

(2010) Jun Kang et al.   Journal of Breast Cancer

Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?

(2010) Pradip De et al.   JOURNAL OF CLINICAL ONCOLOGY

Automated Silver-enhanced In Situ Hybridization for Evaluation of HER2 Gene Status in Breast Carcinoma: Comparison with Fluorescence In Situ Hybridization and Immunohistochemistry

(2010) Woo Jung Sung et al.   Korean Journal of Pathology

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer

(2009) Bert van der Vegt et al.   MODERN PATHOLOGY

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST